Targeting CXCR4/CXCL12 axis via [177Lu]Lu-DOTAGA.(SA.FAPi)2 with CXCR4 antagonist in triple-negative breast cancer
ConclusionThe combination of [177Lu]Lu-DOTAGA.(SA.FAPi)2 and AMD3100 is a feasible treatment against TNBC with minimal toxicity in main organs.
Source: European Journal of Nuclear Medicine and Molecular Imaging - Category: Nuclear Medicine Source Type: research
More News: Breast Cancer | Cancer | Cancer & Oncology | Cardiology | CT Scan | Databases & Libraries | Heart | Liver | Nuclear Medicine | PET Scan | Toxicology | Urology & Nephrology